Skip to main content

Table 2 AD pathology in the different CJD subtypes and strains

From: The characterization of AD/PART co-pathology in CJD suggests independent pathogenic mechanisms and no cross-seeding between misfolded Aβ and prion proteins

  Histotypes, n (%) Strains, n (%)
MM(V)1 VV2 MV2K Other p M1 V2 Other p
ABC score
 Not 117 (35.6) 29 (47.5) 15 (39.5) 12 (54.5) 0.326 117 (35.6) 44 (44.4) 12 (54.5) 0.178
 Low 182 (55.3) 29 (47.5) 21 (55.3) 8 (36.4) 182 (55.3) 50 (50.5) 8 (36.4)
 Intermediate/High 30 (9.1) 3 (4.9) 2 (5.3) 2 (9.1) 30 (9.1) 5 (5.1) 2 (9.1)
Thal phase
 0 117 (35.6) 29 (47.5) 15 (39.5) 12 (54.5) 0.251 117 (35.6) 44 (44.4) 12 (54.5) 0.087
 1–2 99 (30.1) 15 (24.6) 13 (34.2) 6 (27.3) 99 (30.1) 28 (28.3) 6 (27.3)
 3 69 (21.0) 12 (19.7) 8 (21.1) 69 (20.1) 20 (20.2)
 4–5 44 (13.4) 5 (8.2) 2 (5.3) 4 (18.2) 44 (13.4) 7 (7.1) 4 (18.2)
CAA
 not CAA 229 (69.6) 47 (77.0) 29 (76.3) 17 (77.3) 0.519 229 (69.6) 76 (76.8) 17 (77.3) 0.330
 CAA 100 (30.4) 14 (23.0) 9 (23.7) 5 (22.7) 100 (30.4) 23 (23.2) 5 (22.7)
Braak stage
 0 − + 163 (49.5) 38 (62.3) 28 (73.7) 13 (59.1) 0.089 163 (49.5) 66 (66.7) 13 (59.1) 0.045
 I-II 126 (38.3) 18 (29.5) 8 (21.1) 6 (27.3) 126 (38.3) 26 (26.3) 6 (27.3)
 > III 40 (12.2) 5 (8.2) 2 (5.3) 3 (13.6) 40 (12.2) 7 (7.1) 3 (13.6)
 n 329 61 38 22   329 99 22